Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Xu

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
BMC Psychiatry|November 2, 2015
Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalationAntony Loebel, Leslie Citrome, Christoph U Correll, et al.
Journal of Psychiatric Research|February 21, 2013
Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled studyHenry A Nasrallah, Robert Silva, Debra Phillips, et al.
The Journal of Trauma and Acute Care Surgery|February 22, 2023
National trends and clinical outcomes of interventional approaches following admission for infected necrotizing pancreatitis in the United StatesZachary Tran, Jane Xu, Arjun Verma, et al.
The American Journal of Psychiatry|October 31, 2013
Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled studyAntony Loebel, Josephine Cucchiaro, Robert Silva, et al.
BMC Psychiatry|May 7, 2020
Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label studyGreg W Mattingly, Peter M Haddad, Michael Tocco, et al.
Molecular and Biochemical Parasitology|August 8, 2002
The kinetics of uptake and accumulation of 3,6-bis-omega-diethylamino-amyloxyxanthone by the human malaria parasite Plasmodium falciparumJane Xu Kelly, R W Winter, Anda Cornea, et al.
Journal of Medicinal Chemistry|September 1, 2006
A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparumSteven J Burgess, Audrey Selzer, Jane Xu Kelly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2015
Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or TaxanesBoris Shor, Jennifer Kahler, Maureen Dougher, et al.
Precision Clinical Medicine|April 3, 2023
Dysregulated miRNAs modulate tumor microenvironment associated signaling networks in pancreatic ductal adenocarcinomaTiantian Liu, Zhong Chen, Wanqiu Chen, et al.
Molecular and Biochemical Parasitology|January 30, 2003
Antileishmanial drug development: exploitation of parasite heme dependencyJane Xu Kelly, Marina V Ignatushchenko, H G Bouwer, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
BMC Psychiatry|November 2, 2015
Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalationAntony Loebel, Leslie Citrome, Christoph U Correll, et al.
Journal of Psychiatric Research|February 21, 2013
Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled studyHenry A Nasrallah, Robert Silva, Debra Phillips, et al.
The Journal of Trauma and Acute Care Surgery|February 22, 2023
National trends and clinical outcomes of interventional approaches following admission for infected necrotizing pancreatitis in the United StatesZachary Tran, Jane Xu, Arjun Verma, et al.
The American Journal of Psychiatry|October 31, 2013
Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled studyAntony Loebel, Josephine Cucchiaro, Robert Silva, et al.
BMC Psychiatry|May 7, 2020
Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label studyGreg W Mattingly, Peter M Haddad, Michael Tocco, et al.
Molecular and Biochemical Parasitology|August 8, 2002
The kinetics of uptake and accumulation of 3,6-bis-omega-diethylamino-amyloxyxanthone by the human malaria parasite Plasmodium falciparumJane Xu Kelly, R W Winter, Anda Cornea, et al.
Journal of Medicinal Chemistry|September 1, 2006
A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparumSteven J Burgess, Audrey Selzer, Jane Xu Kelly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 31, 2015
Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or TaxanesBoris Shor, Jennifer Kahler, Maureen Dougher, et al.
Precision Clinical Medicine|April 3, 2023
Dysregulated miRNAs modulate tumor microenvironment associated signaling networks in pancreatic ductal adenocarcinomaTiantian Liu, Zhong Chen, Wanqiu Chen, et al.
Molecular and Biochemical Parasitology|January 30, 2003
Antileishmanial drug development: exploitation of parasite heme dependencyJane Xu Kelly, Marina V Ignatushchenko, H G Bouwer, et al.
Pageof 5